Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC_EX:A61K39/44 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.0930316Oral product for the prevention and treatment of infectious gastroenteritides in calves
EP 21.07.1999
Int.Class A61K 39/108
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
108Escherichia; Klebsiella
Appl.No 98310267 Applicant MEDIPHARM CZ S R O Inventor MICAN PETR
Oral product for the prevention and therapy of infectious gastroenteritis in calves that contents of antibodies to bovine rotavirus, bovine coronavirus and enterotoxigenic strains of Escherichia coli prepared from colostrum of immunized cows and/or egg yolks of immunized hens. It contents also a stabilized live culture of lactacidogenic bacteria. Method of production of antibodies to bovine rotavirus, bovine coronavirus and enterotoxigenic strains of Escherichia coli by immunization of cows and/or hens with antigens of bovine rotavirus, bovine coronavirus and enterotoxigenic strains of Escherichia coli, collection of colostrum from the immunized cows and/or egg yolks from the immunized hens and processing of these semi-products into the administration form, for instance by drying.
2.20080299138Toll-Like Receptor 3 Modulators and Uses Thereof
US 04.12.2008
Int.Class A61K 39/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
44Antibodies bound to carriers
Appl.No 12126150 Applicant DUFFY KAREN E Inventor Duffy Karen E.

Modulators of TLR3 activity and their use are disclosed.

3.WO/2006/094269ANTI-ANGIOGENIC COMPOUNDS
WO 08.09.2006
Int.Class A61K 38/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
08Peptides having 5 to 11 amino acids
Appl.No PCT/US2006/007865 Applicant COVX TECHNOLOGIES IRELAND LIMITED Inventor BRADSHAW, Curt, W.
The present invention provides AA targeting compounds which comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to treat disorders connected to abnormal angiogenesis.
4.WO/2014/079000BISPECIFIC ANTIBODY
WO 30.05.2014
Int.Class C07K 16/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
Appl.No PCT/CN2012/084982 Applicant WUHAN YZY BIOPHARMA CO., LTD. Inventor ZHOU, Pengfei
Provided are bispecific antibodies comprised of a single-chain unit having specificity to an immune cell and a monovalent unit having specificity to a tumor cell or a microorganism. The single-chain unit includes a single-chain variable fragment (scFv) fused to an Fc fragment and the monovalent unit includes a light chain and heavy chain pair. Also provided are methods of preparing bispecific antibodies and pharmaceutical and diagnostic uses of these antibodies.
5.WO/2020/023310COMPOSITIONS OF FCRN ANTIBODIES AND METHODS OF USE THEREOF
WO 30.01.2020
Int.Class A61K 31/7016
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7016Disaccharides, e.g. lactose, lactulose
Appl.No PCT/US2019/042597 Applicant MOMENTA PHARMACEUTICALS, INC. Inventor ZHANG, Zhongli
Stable pharmaceutical compositions containing an anti-FcRn antibody are described and characterized.
6.WO/2009/051265STABILISATION OF ANTIBODIES ON HAZARDOUS SUBTANCE-REMOVING MATERIAL AND METHOD OF REMOVING HAZARDOUS SUBSTANCES
WO 23.04.2009
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/JP2008/069073 Applicant FUJIFILM CORPORATION Inventor IWANAGA, Hiroshi
A hazardous substance-removing material which comprises a support having antibodies supported thereon, in which at least one member selected from the group consisting of sugars, amino acids, SH group-protecting agents, and surfactants is incorporated as an antibody-stabilizing agent, in which the antibodies are highly stable, is provided.
7.20110274701COMPOSITION AND METHOD FOR PREVENTING/DECREASING RESPIRATORY ILLNESS
US 10.11.2011
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No 13103559 Applicant Camas Incorporated Inventor Mitteness Bradley M.

A microbial adherence inhibitor in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment of adherence of colony-forming immunogens in the respiratory tracts of host animals and humans. The inhibitor is made by inoculating female birds with the immunogen, harvesting the eggs which contain antibodies to the immunogen, and separating the yolk and albumin from the shells of the eggs. The yolk and albumin contents are administered to animals or human by distributing the contents directly or introducing the contents entrained in air. The adherence inhibiting material can be formulated for use in a variety of ways such as an oral spray or a nasal spray. These formulations can be effective to prevent or reduce respiratory illnesses in animals and humans.

8.20150175711Anti-CD22 anti-idiotypic antibodies and uses thereof
US 25.06.2015
Int.Class C07K 16/42
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
42against immunoglobulins (anti-idiotypic antibodies)
Appl.No 14407988 Applicant SINOMAB BIOSCIENCE LIMITED Inventor Shui-on Leung

The present invention describes the generation of an anti-idiotype single-chain Fv (scFv) antibody specific for the murine (RFB4), chimeric (SM03) and humanized (SM06) versions of an anti-CD22 antibody (the anti-CD22 antibodies). The present invention further describes the construction of a murine IgG2a/kappa immunoglobulin carrying the variable region sequences of the anti-idiotype scFv sequences. Additionally, the present invention provides a cell line capable of producing an anti-idiotype murine antibody specific for the anti-CD22 antibodies. The present invention is directed against a method for identifying and evaluating the activities and concentration of the anti-CD22 antibodies. Additionally, the present invention provides a method for evaluating serum concentration of the anti-CD22 antibodies that are being used clinically. The present invention is also directed against a method to detect HAMA, HACA and HAHA responses in patients treated with the anti-CD22 antibodies. Specifically, the present invention is directed against the establishment of a cell line expressing surface concentration of the antibody of the invention; the said cell line expressing surface anti-idiotype antibodies or antibody fragments will be used as the target cell line for evaluating the functional activities of the anti-CD22 antibodies via complement dependent cytotoxicity (CDC) and/or antibody dependent cell cytotoxicity (ADCC) activities.

9.20160363597Cell lines expressing surface bound anti-idiotype antibodies against anti-CD22 antibodies and uses thereof
US 15.12.2016
Int.Class C12P 21/06
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
21Preparation of peptides or proteins
06produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
Appl.No 15186999 Applicant SINOMAB BIOSCIENCE LIMITED Inventor Shui-on Leung

The present invention describes the generation of an anti-idiotype single-chain Fv (scFv) antibody specific for the murine (RFB4), chimeric (SM03) and humanized (SM06) versions of an anti-CD22 antibody (“the anti-CD22 antibodies”). The present invention further describes the construction of a murine IgG2a/kappa immunoglobulin carrying the variable region sequences of the anti-idiotype scFv sequences. Additionally, the present invention provides a cell line capable of producing an anti-idiotype murine antibody specific for “the anti-CD22 antibodies.” The present invention is directed against a method for identifying and evaluating the activities and concentration of “the anti-CD22 antibodies.” Additionally, the present invention provides a method for evaluating serum concentration of “the anti-CD22 antibodies” that are being used clinically. The present invention is also directed against a method to detect HAMA, HACA and HAHA responses in patients treated with “the anti-CD22 antibodies.” Specifically, the present invention is directed against the establishment of a cell line expressing surface concentration of the antibody of the invention; the said cell line expressing surface anti-idiotype antibodies or antibody fragments will be used as the target cell line for evaluating the functional activities of “the anti-CD22 antibodies” via complement dependent cytotoxicity (CDC) and/or antibody dependent cell cytotoxicity (ADCC) activities.

10.2138131SUBSTRATE FOR FLUOROASSAY OF BIOLOGICAL FLUIDS
GB 15.02.1984
Int.Class C08L 33/00
CCHEMISTRY; METALLURGY
08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
33Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Compositions of derivatives of such polymers
Appl.No 8400807 Applicant DARYL LAB INC Inventor HARTE RICHARD A